Revised Page 5 Award Document - SPE2D223D0003.pdf

PDF 181 KB Posted

Attached to
Hydrochlorothiazide Federal contract opportunity
Solicitation number
SPE2D2-23-D-0003
Issued by
Defense Logistics Agency Troop Support Medical

View the file

Other files for this federal contract opportunity

Other files attached to Hydrochlorothiazide, newest first.
File Type Posted
SF30_SPE2D223D0003P00005.PDF Signed.pdf PDF
Signed SPE2D223D0003 P00004.pdf PDF
Signed SPE2D223D0003 P00002.PDF PDF
Bilaterally Signed SPE2D223D0003 P00001.pdf PDF
Bilaterally Signed REVISED Hydrochlorothiazide Award SPE2D2-23-D-0003.pdf PDF

On GovTribe

Work with this file on GovTribe

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

Continuation of SF 1449…

1. This contract is estimated at $10,219,342.40 (5 years) or $2,043,868.48 (per year) based on the projected demand.

2. Pursuant to FAR 52.215-6, the Place of Manufacture/Performance is as follows:

☐OFFEROR IS THE MANUFACTURER (AT THE FOLLOWING LOCATIONS) OF THE

PRODUCTS OFFERED ON THIS SOLICITATION.

☒OFFEROR IS A DISTRIBUTOR OF THE PRODUCTS OFFERED ON THIS SOLICITATION. THE

PRODUCTS WILL BE MANUFACTURED BY THE FOLLOWING COMPANY AT THE

FOLLOWING LOCATIONS:

Leading Pharma, LLC

(Name of Manufacturing Company)

3 Oak Road, Fairfield, NJ 07004 (Street Address) (Post Office Address Not Acceptable)

Doug Statler, dstatler@leadingpharma.com, 480-268-1274 (U.S.A. Point of Contact, e-Mail Address and U.S.A Telephone Number)

TABLETS, CAPSULES AND PILLS

Item Complete Address of Facility

Where Ingredients are

Measured, Weighed, Mixed and Compounded

Point of Contact

Including Phone Number

0001 – Hydrochlorothiazide 25

MG Tablet – 90 Count Bottle

Leading Pharma

3 Oak Road

Fairfield, NJ 07004

Doug Statler

480-268-1274

0002 – Hydrochlorothiazide 25

MG Tablet – 100 Count Bottle

0003 – Hydrochlorothiazide 25

MG Tablet – 1000 Count Bottle

0004 – Hydrochlorothiazide 50

MG Tablet – 90 Count Bottle mailto:dstatler@leadingpharma.com

File details come from the government source that posted it. Updated .